NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in C
Go back to NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in C| (NASDAQ: ELAB) | Delayed: 1.35 -0.04 (2.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.39 | 52 Week High | $ | |||
| Open | $1.38 | 52 Week Low | $ | |||
| Day High | $1.41 | P/E | N/A | |||
| Day Low | $1.34 | EPS | $ | |||
| Volume | 287,208 | |||||
